Aadi Bioscience AADI
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Aadi Bioscience (AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Key Insights
Critical company metrics and information
Latest Closing Price
$2.12Market Cap
$98.13 MillionPrice-Earnings Ratio
-4.61Total Outstanding Shares
24.70 Million SharesTotal Employees
53Dividend
No dividendIPO Date
August 27, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
17383 sunset avenue, Pacific palisades, CA, 90272Homepage
https://www.aadibio.com
Historical Stock Splits
If you bought 1 share of AADI before August 31, 2005, you'd have 5.63 shares today.
| Execution Date | Split Amount |
|---|---|
| December 18, 2007 | 4.5-for-1 |
| August 31, 2005 | 5-for-4 |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-10.60 Million |
| Net Cash Flow From Financing Activities, Continuing | $0 |
| Net Cash Flow From Investing Activities, Continuing | $5.08 Million |
| Net Cash Flow From Operating Activities | $-15.69 Million |
| Net Cash Flow From Operating Activities, Continuing | $-15.69 Million |
| Net Cash Flow | $-10.60 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $20.63 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Basic Average Shares | $27.04 Million |
| Gross Profit | $6.41 Million |
| Operating Income/Loss | $-13.41 Million |
| Revenues | $7.21 Million |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-12.48 Million |
| Comprehensive Income/Loss | $-12.48 Million |
| Other Comprehensive Income/Loss | $-12.48 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $68.87 Million |
| Fixed Assets | $5.98 Million |
| Noncurrent Liabilities | $1.02 Million |
| Liabilities | $16.83 Million |
| Accounts Payable | $1.37 Million |
| Inventory | $5.47 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about AADI from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.